ABSTRACT
Atherosclerotic cardiovascular disease (ACVD) is a lipid-driven inflammatory disease and one of the leading causes of death worldwide. Lipid deposits in the arterial wall lead to the formation of plaques that involve lipid oxidation, cellular necrosis, and complement activation, resulting in inflammation and thrombosis. The present study found that homozygous deletion of the CFHR1 gene, which encodes the plasma complement protein factor H-related protein 1 (FHR-1), was protective in two cohorts of patients with ACVD, suggesting that FHR-1 accelerates inflammation and exacerbates the disease. To test this hypothesis, FHR-1 was isolated from human plasma and was found to circulate on extracellular vesicles and to be deposited in atherosclerotic plaques. Surface-bound FHR-1 induced the expression of pro-inflammatory cytokines and tissue factor in both monocytes and neutrophils. Notably, plasma concentrations of FHR-1, but not of factor H, were significantly (p < 0.001) elevated in patients with ACVD, and correlated with the expression of the inflammation markers C-reactive protein, apolipoprotein serum amyloid protein A, and neopterin. FHR-1 expression also significantly correlated with plasma concentrations of low-density lipoprotein (LDL) (p < 0.0001) but not high-density lipoprotein (HDL). Taken together, these findings suggest that FHR-1 is associated with ACVD.
Subject(s)
Atherosclerosis/metabolism , Cardiovascular Diseases/metabolism , Complement C3b Inactivator Proteins/physiology , Gene Expression Regulation , Aged , Cardiology , Chromosome Deletion , Complement Activation , Complement C3b Inactivator Proteins/biosynthesis , Complement C3b Inactivator Proteins/genetics , Female , Gene Expression Profiling , Homozygote , Humans , Inflammation , Lipids/chemistry , Male , Middle Aged , Necrosis , Oxygen/chemistry , Sequence DeletionABSTRACT
Persistent inflammation is a hallmark of many human diseases, including anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) and atherosclerosis. Here, we describe a dominant trigger of inflammation: human serum factor H-related protein FHR1. In vitro, this protein selectively binds to necrotic cells via its N-terminus; in addition, it binds near necrotic glomerular sites of AAV patients and necrotic areas in atherosclerotic plaques. FHR1, but not factor H, FHR2 or FHR3 strongly induces inflammasome NLRP3 in blood-derived human monocytes, which subsequently secrete IL-1ß, TNFα, IL-18 and IL-6. FHR1 triggers the phospholipase C-pathway via the G-protein coupled receptor EMR2 independent of complement. Moreover, FHR1 concentrations of AAV patients negatively correlate with glomerular filtration rates and associate with the levels of inflammation and progressive disease. These data highlight an unexpected role for FHR1 during sterile inflammation, may explain why FHR1-deficiency protects against certain diseases, and identifies potential targets for treatment of auto-inflammatory diseases.
Subject(s)
Complement C3b Inactivator Proteins/metabolism , Inflammasomes/metabolism , Monocytes/metabolism , Monocytes/pathology , Vascular Diseases/metabolism , Vascular Diseases/pathology , C-Reactive Protein/metabolism , Complement System Proteins/metabolism , Human Umbilical Vein Endothelial Cells/metabolism , Humans , Immobilized Proteins/metabolism , Inflammation/metabolism , Inflammation/pathology , Inflammation Mediators/metabolism , Interleukin-1beta/metabolism , Lipoproteins, LDL/metabolism , Malondialdehyde/metabolism , Models, Biological , NLR Family, Pyrin Domain-Containing 3 Protein/metabolism , Necrosis , Protein Binding , Receptors, G-Protein-Coupled/metabolism , Serum/metabolism , Type C Phospholipases/metabolismABSTRACT
The complement system is a central part of the innate immune system. It defends the human body against infections and helps with the clearance of apoptotic particles and cellular debris. The importance of the complement system in physiology is reflected by autoreactive diseases that occur due to loss of functions of complement regulators as identified in age-related macular degeneration or gain of functions in complement convertases like C3 glomerulopathy. The chapter aims to provide methods to study complement regulation on a molecular level. Here we describe a set of in vitro assays, the combined techniques of ELISA and immunoblotting, to determine complement activation and regulation on surfaces. The methods allow to follow part of the complement activation cascade and to determine the activity of complement regulators like factor H.
Subject(s)
Blotting, Western , Cell Membrane/immunology , Complement Activation/immunology , Complement System Proteins/immunology , Enzyme-Linked Immunosorbent Assay , Cell Membrane/metabolism , Complement System Proteins/metabolism , HumansABSTRACT
The human plasma contact system is an immune surveillance system activated by the negatively charged surfaces of bacteria and fungi and includes the kallikrein-kinin, the coagulation, and the fibrinolytic systems. Previous work shows that the contact system also activates complement, and that plasma enzymes like kallikrein, plasmin, thrombin, and FXII are involved in the activation process. Here, we show for the first time that kallikrein cleaves the central complement component C3 directly to yield active components C3b and C3a. The cleavage site within C3 is identical to that recognized by the C3 convertase. Also, kallikrein-generated C3b forms C3 convertases, which trigger the C3 amplification loop. Since kallikrein also cleaves factor B to yield Bb and Ba, kallikrein alone can trigger complement activation. Kallikrein-generated C3 convertases are inhibited by factor H; thus, the kallikrein activation pathway merges with the amplification loop of the alternative pathway. Taken together, these data suggest that activation of the contact system locally enhances complement activation on cell surfaces. The human pathogenic microbe Candida albicans activates the contact system in normal human serum. However, C. albicans immediately recruits factor H to the surface, thereby evading the alternative and likely kallikrein-mediated complement pathways.
Subject(s)
Complement Activation , Complement C3-C5 Convertases/metabolism , Complement C3/metabolism , Kallikreins/metabolism , Amino Acid Sequence , Animals , Candida albicans/immunology , Candidiasis/immunology , Candidiasis/microbiology , Cell Line, Transformed , Complement C3b/chemistry , Complement C3b/metabolism , Complement Factor B/metabolism , Complement Factor D/metabolism , Complement Factor H/pharmacology , Complement Pathway, Alternative , Factor XII/metabolism , Female , Humans , Immune Evasion , Mice, Inbred BALB C , Protein Binding/drug effectsABSTRACT
Cancer is a disease associated with genomic instability that often results from oncogene activation. This in turn leads to hyperproliferation and replication stress. However, the molecular mechanisms that underlie oncogene-induced replication stress are still poorly understood. Oncogenes such as HRASV12 promote proliferation by upregulating general transcription factors to stimulate RNA synthesis. Here we investigate whether this increase in transcription underlies oncogene-induced replication stress. We show that in cells overexpressing HRASV12, elevated expression of the general transcription factor TATA-box binding protein (TBP) leads to increased RNA synthesis, which together with R-loop accumulation results in replication fork slowing and DNA damage. Furthermore, overexpression of TBP alone causes the hallmarks of oncogene-induced replication stress, including replication fork slowing, DNA damage and senescence. Consequently, we reveal that increased transcription can be a mechanism of oncogene-induced DNA damage, providing a molecular link between upregulation of the transcription machinery and genomic instability in cancer.
